Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Old 07-29-2003, 04:57 AM   #1
Posts: n/a
Monitoring the progress of Introgen's INGN 241 appears valuable because in 2002 data from preclinical studies indicated that INGN 241 acts by suppressing growth of a number of malignant tumors including melanoma and brain breast colon lung and prostate cancer. INGN 241 does not affect growth of normal cells. In addition it stimulated immune cells and acted as a radiosensitizer. INGN 241 in combination with chemotherapeutic products Adriamycin® Taxotere® Tamoxifen® and Herceptin® was shown to display supra- additive effects in inhibiting breast cancer growth and inducing cancer cell death.

The cross-link below is a press release related to findings presented at the 2003 annual meeting of the American Association of Cancer Research held earlier this month.
  Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump

All times are GMT -7. The time now is 06:11 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2020, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter